Literature DB >> 23054653

Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea.

Vikas Dua1, Satya Prakash Yadav, Vijay Kumar, Renu Saxena, Anupam Sachdeva.   

Abstract

Thrombocytosis is common in infancy and childhood. Essential thrombocythemia (ET), a myeloproliferative disorder, is a much less common cause of thrombocytosis in childhood. We report two cases of essential thrombocythemia in 5- and 10-year-old children, who presented with platelet counts of more than 1,000,000/mm(3). Treatment is not recommended for ET in an asymptomatic patient in the absence of bleeding or thrombosis and a platelet count <1,500,000/mm(3). Our first case had platelets >1,500,000/mm(3), and a second child was symptomatic with recurrent headache. Both responded well to therapy with hydroxyurea (dose 15-30 mg/kg/day) and tolerated it well.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23054653     DOI: 10.1007/s12185-012-1193-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  27 in total

1.  Incidence of essential thrombocythaemia in children.

Authors:  H Hasle
Journal:  Br J Haematol       Date:  2000-09       Impact factor: 6.998

2.  Acquired DNA mutations associated with in vivo hydroxyurea exposure.

Authors:  V N Hanft; S R Fruchtman; C V Pickens; W F Rosse; T A Howard; R E Ware
Journal:  Blood       Date:  2000-06-01       Impact factor: 22.113

Review 3.  Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia.

Authors:  Shinsuke Mizutani; Junya Kuroda; Daisuke Shimizu; Shigeo Horiike; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2010-02-11       Impact factor: 2.490

Review 4.  Treatment of essential thrombocythemia with anagrelide.

Authors:  M M Chintagumpala; L L Kennedy; C P Steuber
Journal:  J Pediatr       Date:  1995-09       Impact factor: 4.406

Review 5.  What is the standard treatment in essential thrombocythemia.

Authors:  Tiziano Barbui
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

6.  Thrombocytosis in children at one medical center of southern Taiwan.

Authors:  H L Chen; S S Chiou; J M Sheen; R C Jang; C C Lu; T T Chang
Journal:  Acta Paediatr Taiwan       Date:  1999 Sep-Oct

7.  Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.

Authors:  T R Kinney; R W Helms; E E O'Branski; K Ohene-Frempong; W Wang; C Daeschner; E Vichinsky; R Redding-Lallinger; B Gee; O S Platt; R E Ware
Journal:  Blood       Date:  1999-09-01       Impact factor: 22.113

8.  Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance.

Authors:  Naseema Gangat; Ayalew Tefferi; Gita Thanarajasingam; Mrinal Patnaik; Susan Schwager; Rhett Ketterling; Alexandra P Wolanskyj
Journal:  Eur J Haematol       Date:  2009-02-19       Impact factor: 2.997

9.  Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.

Authors:  S Cortelazzo; G Finazzi; M Ruggeri; O Vestri; M Galli; F Rodeghiero; T Barbui
Journal:  N Engl J Med       Date:  1995-04-27       Impact factor: 91.245

Review 10.  Drug-induced thrombocytosis.

Authors:  J L Frye; D F Thompson
Journal:  J Clin Pharm Ther       Date:  1993-02       Impact factor: 2.512

View more
  2 in total

Review 1.  Primary thrombocytosis in children.

Authors:  Nicole Kucine; Katherine M Chastain; Michelle B Mahler; James B Bussel
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

2.  Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review.

Authors:  Jean-Christophe Ianotto; Natalia Curto-Garcia; Marie Lauermanova; Deepti Radia; Jean-Jacques Kiladjian; Claire N Harrison
Journal:  Haematologica       Date:  2019-01-24       Impact factor: 9.941

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.